Anthem Biosciences logo

Anthem Biosciences financials and balance sheet

NSE: ANTHEMBSE: 544449Pharmaceuticals & BiotechnologyMid Cap

Last close ₹812.80up ₹12.05 (1.50%)BSE ₹812.15

Share price at the NSE close on 23 Oct 2026. Previous close ₹800.75.

52-week range of traded prices to 23 Oct 2026
₹579.15Low, 2 Feb 2026₹977.55High, 9 Sep 2026
Market cap
₹45,804 Cr226th largest listed
P/E
79.5
P/B
15.1
Dividend yield
0.25%
ROE
18.9%
ROCE
21.2%
Debt to equity
0.02
Volume, NSE
5,35,89649.5% delivered

1 year at a glance

Consolidated: the company and its subsidiaries together. ₹ crore, years to March.Anthem Biosciences annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Consolidated: the company and its subsidiaries together. ₹ crore.

From revenue to net profit

  1. Revenue2,124
  2. Materials and goods−812
  3. Employee costs−283
  4. Other expenses−196
  5. Operating profit834
  6. Depreciation−134
  7. Other income+156
  8. One-off items−24
  9. Finance costs−6.9
  10. Profit before tax824
  11. Tax−232
  12. Net profit592

What the company owns

  • Plant, investments and other assets₹1,774 Cr
  • Current investments₹666 Cr
  • Receivables₹591 Cr
  • Cash and bank₹275 Cr
  • Inventory₹125 Cr

What pays for it: net worth and liabilities

  • Net worth₹3,043 Cr
  • Other liabilities₹260 Cr
  • Owed to suppliers₹75 Cr
  • Borrowings₹51 Cr

Anthem Biosciences business segments, year to Mar 2026

A reportable segment is a line of business the company must report on its own. Consolidated, ₹ crore, as the company reports them.Anthem Biosciences segment results by quarter

Revenue by segment

₹2,124 CrTotal
  • CRDMO₹1,773 Cr83.5% of total
  • Speciality Ingredients₹352 Cr16.5% of total

Profit by segment

  • CRDMO₹1,133 Cr86.4% of total
  • Speciality Ingredients₹179 Cr13.6% of total

Segment results by year

Consolidated, ₹ crore, years to March.

  • CRDMO

    Revenue, ₹ crore
    Profit, ₹ crore
  • Speciality Ingredients

    Revenue, ₹ crore
    Profit, ₹ crore
₹ croreMar 2026
Revenue of all businesses2,124
Company revenue, as in its results2,124
Revenue1,773
Profit1,133
Margin63.9%
Revenue352
Profit is before tax and finance costs, the way companies report their segments.

Profit and loss

Consolidated, ₹ crore, years to March.Anthem Biosciences quarterly results

₹ croreMar 2026Filed 21 Sep
Revenue from operations2,124
1,291
Materials and goods bought812
Employee costs283
Other expenses196
Operating profit before depreciation834
Operating margin39.3%
Materials, % of revenue38.2%
Employee costs, % of revenue13.3%
Other expenses, % of revenue9.2%
Depreciation and amortisation134
Operating profit after depreciation700
Other income156
Finance costs7
Profit before one-off items and tax849
One-off items−24
Profit before tax824
232
Net profit592
Other comprehensive income−2
Total comprehensive income590
Net margin27.9%

Balance sheet

Consolidated, ₹ crore, at 31 March.

₹ croreMar 2026Filed 21 Sep
3,043
Share capital112
Reserves2,930
51
326
61
Total assets3,429
1,626
1,803
Net debt−889
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Consolidated, ₹ crore, years to March.

₹ croreMar 2026Filed 21 Sep
844
1,121
139
Receivables−126
Inventories216
Payables−35
Other working capital84
Tax paid−204
Interest paid7
Capital spending211
Free cash flow633
−702
−40
Dividends paid0
Shares bought back0
Shares issued27
Net change in cash103
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Consolidated, ₹ per share, years to March.Anthem Biosciences dividend history

₹ per shareMar 2026Filed 21 Sep
Earnings per share₹10.55
Diluted earnings per share₹10.43
Dividend per share₹2.00
Book value per share₹54.16
Dividend payout19.0%
Shareholder yield−0.1%
Market cap at the year end (₹ crore)36,856

Ratios

Consolidated, years to March.Anthem Biosciences PE ratio and valuation

RatioMar 2026Filed 21 Sep
Return on equity19.5%
Return on capital employed22.6%
Cash conversion142.7%
Interest cover101.5
Debt to equity0.02
Receivable days101
Inventory days56
Payable days34
Cash conversion cycle, days124
Working capital days96
Asset turnover0.62
Assets per rupee of net worth1.13
Sales per rupee of plant2.72
Capital spending to depreciation1.58
Plant being built, % of plant in use33.9%

Growth and returns over 3, 5 and 10 years

Consolidated: the company and its subsidiaries together. Each window ends with the year to Mar 2026.

Return on assets, latest year
17.3%
Cash from operations against operating profit
101.3%

Where the cash came from and went

Consolidated: the company and its subsidiaries together. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations844
Cash from investing−702
Cash from financing−40
Capital spending211
Dividends paid0
Shares bought back0
Shares issued for cash27
Borrowings raised0
Borrowings repaid58

Accounting checks

Consolidated, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Altman Z-scorePublished threshold 1.8160.32
Effective tax ratePublished threshold 17.16 per cent28.20
Tax charged less tax paid, % of profitOur threshold 10 percentage points3.45
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
2 Jul 2026ICRA Limited (opens in a new tab)Unallocated limits-Unallocated limits[ICRA]AA /[ICRA]A1+Review, UpgradeStable23
2 Jul 2026ICRA Limited (opens in a new tab)Fund-based-Cash credit[ICRA]AA /[ICRA]A1+Review, UpgradeStable175
2 Jul 2026ICRA Limited (opens in a new tab)Non-fund based-Others[ICRA]A1+New, New10
2 Jul 2026ICRA Limited (opens in a new tab)Fund-based-Term loan[ICRA]AAReview, UpgradeStable67.50
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.